Transforming into a high single digit growth company from FY 2022 onwards

Key Messages Capital Markets Day

From Mid to

High single digit

sales growth

FY 2020e: guidance confirmed

FY 2021e: mid single digit (3-7%)

From FY 2022e onward: high single digit (6-9%)

Growth push through

High Value

Solutions

For both segments pharma and cosmetics

Biologics vials and syringes

ELITE® Glass

Ready-to-fill products (RTF)

Decorated glass and PCR glass

Strong growth drivers, starting in 2021:

Gx Biologic Solutions

EBITDA margin:

steady increase with

good trajectory

Investments into

Business Opportunities

Base Capex

4%

Growth Capex

5%

Unique

Business

~3%

Opportunities

  • ELITE® Glass CAGR >30%; RTF Vials CAGR >50%
  • More than double sales with high value solutions
  • Triple sales in biologics by 2028

FY 2020e: 22% without GAT

FY 2021e: 22-23% | Mid-term: comfortable 23%

  • Product mix: ramp-up for high value solutions
  • Excellence and efficiency initiatives
  • Economies of scale

Disciplined value generative oriented capital allocation: ROCE target 15% - every single project will contribute

Seizing unique business opportunities by capacity expansion in injectables: IRR ~25%

Capex is not Capex - significant portion into low risk investments with excellent upside potential: contract manufacturing new auto injector contract (> IRR 25%)

GAT

(incl. Sensile)

Gerresheimer's innovation hub

Call option - Break Even expected for 2023

  • Conservative approach: excl. GAT from Guidance
  • Continuously good trajectory in projects, break even in FY 2023 expected
  • SQ Innovation on track with good progress, first significant sales in 2022

12/9/2020 CMD Fact Sheet

Attachments

  • Original document
  • Permalink

Disclaimer

Gerresheimer AG published this content on 10 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 December 2020 09:48:06 UTC